In brief: Ponatinib (Iclusig) marketing and sales suspended

Medical Letter on Drugs and Therapeutics

Volumn 55, Issue 1430, 2013, Pages 93-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PONATINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTERY THROMBOSIS; BLINDNESS; BLOOD CLOT; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG FATALITY; DRUG LABELING; DRUG MARKETING; DRUG RECALL; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HEART FAILURE; HUMAN; LETTER; PRODUCT SAFETY; VASOCONSTRICTION;

EID: 84888103974     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. FDA Drug Safety Communication: FDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales. Available at www.fda.gov/Drugs/DrugSafety/ucm373040. htm. Accessed November 18, 2013.
2. Ponatinib (Iclusig) for CML and Ph+ ALL. Med Lett Drugs Ther 2013; 55:71.
3. JH Doroshow. Overcoming resistance to targeted anticancer drugs. N Engl J Med 2013; 369:1852.
4. Ariad expects narrower label, not withdrawal, for Iclusig following halted study. "The Pink Sheet" 2013; 75:16.